News Channels

18 Oct 2017 Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
18 Oct 2017 Synspira Announces First Patient Dosed in Phase 1a Study of SNSP113 in Cystic Fibrosis
18 Oct 2017 Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
18 Oct 2017 Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients
18 Oct 2017 Vir Biotechnology Builds Pipeline, Capabilities, and Lays Out Strategy to Address Serious Infectious Diseases
18 Oct 2017 U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review
18 Oct 2017 AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration
18 Oct 2017 Merck’s KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with High Levels of PD-L1
18 Oct 2017 Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines
17 Oct 2017 Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors
17 Oct 2017 Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Esophageal Cancer
17 Oct 2017 MEBIAS Discovery LLC Presents Pre-Clinical Data on Mu Opioid Receptor Pain Compounds at ADDC
17 Oct 2017 Dicerna Files Clinical Trial Application for DCR-PHXC, the Company’s Most Advanced GalXC™ Product Candidate, for Phase 1 Study in Primary Hyperoxaluria (PH)
17 Oct 2017 Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
17 Oct 2017 ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active
17 Oct 2017 Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases
17 Oct 2017 Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA
17 Oct 2017 Incysus Announces FDA Approval of IND Application for a Phase 1 Study of a Gamma-Delta (γδ) T Cell Leukemia and Lymphoma Immunotherapy
17 Oct 2017 ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease
17 Oct 2017 AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing